[go: up one dir, main page]

BRPI0507436A - conjugados antagonistas de receptor do hormÈnio do crescimento humano quimicamente modificados - Google Patents

conjugados antagonistas de receptor do hormÈnio do crescimento humano quimicamente modificados

Info

Publication number
BRPI0507436A
BRPI0507436A BRPI0507436-3A BRPI0507436A BRPI0507436A BR PI0507436 A BRPI0507436 A BR PI0507436A BR PI0507436 A BRPI0507436 A BR PI0507436A BR PI0507436 A BRPI0507436 A BR PI0507436A
Authority
BR
Brazil
Prior art keywords
chemically modified
human growth
modified human
growth hormone
receptor antagonist
Prior art date
Application number
BRPI0507436-3A
Other languages
English (en)
Inventor
Thomas J Girard
Rory F Finn
Ned R Siegel
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of BRPI0507436A publication Critical patent/BRPI0507436A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

CONJUGADOS ANTAGONISTAS DO RECEPTOR DO HORMÈNIO DO CRESCIMENTO HUMANO QUIMICAMENTE MODIFICADOS A presente invenção fornece antagonistas do receptor do hormónio do crescimento humano (hGH) quimicamente modificados preparados anexando um fração de polietileno glicol única ao N-terminal. A proteína quimicamente modificada de acordo com a presente invenção tem menor heterogeneidade de Peguilação e pode ter maior afinidade de ligação.
BRPI0507436-3A 2004-02-09 2005-01-31 conjugados antagonistas de receptor do hormÈnio do crescimento humano quimicamente modificados BRPI0507436A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54307804P 2004-02-09 2004-02-09
PCT/IB2005/000228 WO2005075021A2 (en) 2004-02-09 2005-01-31 Chemically-modified human growth hormone receptor antagonist conjugates

Publications (1)

Publication Number Publication Date
BRPI0507436A true BRPI0507436A (pt) 2007-07-03

Family

ID=34837575

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0507436-3A BRPI0507436A (pt) 2004-02-09 2005-01-31 conjugados antagonistas de receptor do hormÈnio do crescimento humano quimicamente modificados

Country Status (7)

Country Link
US (1) US20090203589A1 (pt)
EP (1) EP1715895A2 (pt)
JP (1) JP2007522198A (pt)
BR (1) BRPI0507436A (pt)
CA (1) CA2553899A1 (pt)
MX (1) MXPA06007848A (pt)
WO (1) WO2005075021A2 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006326404B2 (en) * 2005-12-14 2011-11-03 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
AU2007296190A1 (en) * 2006-09-15 2008-03-20 Enzon Pharmaceuticals, Inc. Lysine-based polymeric linkers
US9717778B2 (en) * 2012-02-03 2017-08-01 Antisense Therapeutics Ltd. Combination therapy
KR102167827B1 (ko) * 2017-12-20 2020-10-20 주식회사 알테오젠 신규한 성장 호르몬 수용체 길항제 및 이의 융합 단백질
WO2020257243A1 (en) 2019-06-17 2020-12-24 Molecular Technologies Laboratories Llc Therapeutic pegylated growth hormone antagonists
WO2025088605A2 (en) * 2023-10-24 2025-05-01 Opko Biologics Ltd. Human growth hormone receptor antagonists and methods of use thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5849535A (en) * 1995-09-21 1998-12-15 Genentech, Inc. Human growth hormone variants
US20030171285A1 (en) * 2001-11-20 2003-09-11 Finn Rory F. Chemically-modified human growth hormone conjugates
PT1545428E (pt) * 2002-09-20 2010-02-25 Pharmacia Corp Processo para diminuir o nível da agregação de uma proteína peguilada
PA8588901A1 (es) * 2002-11-20 2005-02-04 Pharmacia Corp Conjugados de hormona de crecimiento humana pegilados n-terminales y proceso para su preparacion
CA2509248A1 (en) * 2002-12-31 2004-07-22 Nektar Therapeutics Al, Corporation Polymeric reagents comprising a ketone or a related functional group

Also Published As

Publication number Publication date
MXPA06007848A (es) 2006-09-04
WO2005075021A2 (en) 2005-08-18
US20090203589A1 (en) 2009-08-13
EP1715895A2 (en) 2006-11-02
WO2005075021A3 (en) 2006-07-20
JP2007522198A (ja) 2007-08-09
CA2553899A1 (en) 2005-08-18

Similar Documents

Publication Publication Date Title
EP1432433A4 (en) ANTAGONISTS
NO20031179D0 (no) Chemokin-reseptorbindende heterocykliske forbindelser
GB201009493D0 (en) Modified recombinant factor viii and von willebrand factor and methods of use
SI1572967T1 (sl) Antagonisti il-1 receptorja in postopek za izdelavo in uporabo
MXPA06014798A (es) Antagonistas del receptor de hormona para liberar gonadotropina.
DE60231868D1 (de) Folat-mimetika und deren folatrezeptorbindende konjugate
ATE516305T1 (de) Il-15-bindungsstelle für il-15-ralpha und spezifische il-15-mutanten mit wirkung als agonisten/antagonisten
EP2279754A3 (en) Remodelling and glycoconjugation of human growth hormone (hGH)
EP2526968A3 (en) Nogo receptor antagonists
BR122016022033B8 (pt) conjugados de polipeptídeo isolado apresentando atividade pró-coagulante de fator viii, seu uso e composição farmacêutica
IS7677A (is) Mótlyf Nogo-viðtaka
MY169272A (en) Her2 antibody composition
WO2005000877A3 (en) Novel melanocortin receptor templates, peptides, and use thereof
IL177922A0 (en) Modified bouganin proteins, cytotoxins and methods and uses thereof
CY1115295T1 (el) Συνθεση για την θεραπεια παθολογιας συνδεομενης με msrv/herv-w
BRPI0507436A (pt) conjugados antagonistas de receptor do hormÈnio do crescimento humano quimicamente modificados
WO2001072771A3 (en) Insulin and igf-1 receptor agonists and antagonists
WO2006058012A3 (en) Gonadotropin releasing hormone receptor antagonists
JO2859B1 (en) Peptides and compounds that are associated with a receptor
WO2006087163A3 (en) Novel in vitro methods for studying receptors recognizing volatile compounds
WO2007059300A3 (en) Anti-alk antagonist and agonist antibodies and uses thereof
WO2003017938A3 (en) Conjugates targeted to target receptors
DE602004027039D1 (de) Cytokinpolypeptidvarianten
WO2001058484A3 (en) Novel uses of mammalian ccr8 receptors and related reagents
WO2003089582A3 (en) Multimeric ligands with enhanced stability

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A E 6A ANUIDADES

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2099 DE 29/03/2011.

B15K Others concerning applications: alteration of classification

Ipc: A61K 47/48 (2006.01), A61P 5/04 (2006.01)

B15K Others concerning applications: alteration of classification

Ipc: A61K 47/60 (2017.01), A61P 5/04 (2006.01)